ArticleJournal of clinical microbiology2008
Epidemiology of European community-associated methicillin-resistant Staphylococcus aureus clonal complex 80 type IV strains isolated in Denmark from 1993 to 2004.
Article in Journal of clinical microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.Antimicrobial resistance and infection control · 2021Pooled it
- Methicillin-ResistantToxins · 2020Pooled it
- Characterization of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for treatment of nosocomial pneumonia.Journal of clinical microbiology · 2012Trial
- Characterization of baseline methicillin-resistant Staphylococcus aureus isolates recovered from phase IV clinical trial for linezolid.Journal of clinical microbiology · 2010Trial
- Synergistic Anti-Biofilm and Bactericidal Activity of Ethanol and Chlorhexidine Combined with EDTA AgainstInfection and drug resistance · 2026Article
- Understanding the Molecular Epidemiology of Community-Acquired Methicillin-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Article
- Virulence attributes of successful methicillin-resistantClinical microbiology reviews · 2023Review
- Genomic analysis of methicillin-resistantFrontiers in microbiology · 2022Article
- Molecular Characterization ofPathogens (Basel, Switzerland) · 2021Article
- Travel-Related Antimicrobial Resistance: A Systematic Review.Tropical medicine and infectious disease · 2021Review
- Genetic Profiling and Comparison of Human and Animal Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2019Article
- Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology.Clinical microbiology reviews · 2018Review
- Distribution of the Most PrevalentFrontiers in microbiology · 2018Review
- The European Union summary report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2015.EFSA journal. European Food Safety Authority · 2017Article
- Article
- Trends in the Genetic Background of Methicillin-ResistantThe open microbiology journal · 2017Article
- Article
- Origin and evolution of European community-acquired methicillin-resistant Staphylococcus aureus.mBio · 2014Article
- Article
- Community-acquired methicillin-resistant Staphylococcus aureus: the new face of an old foe?Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Europe, community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections have been caused predominantly by isolates belonging to the "European CA-MRSA" clone (sequence type 80, staphylococcal cassette chromosome mec type IV). In this study, the epidemiology of European CA-MRSA was investigated on a nationwide scale, covering the period from 1993 to 2004. Denmark has been a low-prevalence country regarding MRSA since the mid-1970s but has experienced an increase in the number of new MRSA cases in recent years. Our results show that European CA-MRSA contributed to this increase. The isolates primarily caused skin and soft tissue infections (SSTIs) in patients outside hospitals, and transmission between household members was the predominant mode of spread. Although some of the isolates were found in hospitalized patients, nosocomial transmission seemed likely in only one instance, pointing to endogenous infections as an important factor. Compared to the CA-MRSA clone most common in the United States (USA300), the European CA-MRSA clone seems less well adapted to persist in hospital environments. Patients with a recent history of travel or family relation to the Mediterranean or Middle East were highly overrepresented. The epidemiological data indicated that the European CA-MRSA isolates were introduced into Denmark on multiple occasions, paralleled by an increasing level of genetic diversity of the isolates found during the study period. European CA-MRSA has previously been described as a rather uniform clone. However, we found pronounced, diverse pulsed-field gel electrophoresis subtypes, staphylococcal protein A gene (spa) types, and susceptibility patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.